Cytek Biosciences (CTKB) Research & Development (2020 - 2026)

Cytek Biosciences has reported Research & Development for 7 years, with the latest figure at $9.6 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 1.24% year-over-year to $9.6 million; the trailing twelve-month figure through Mar 2026 stood at $36.3 million (down 7.58% YoY), and the FY2025 full-year result was $36.5 million, down 7.45% from the prior year.
• Research & Development for Q1 2026 stood at $9.6 million, up from $9.0 million in the prior quarter.
• The five-year high for Research & Development was $12.1 million in Q2 2023, with the low at $8.0 million in Q1 2022.
• Historically, Research & Development has averaged $9.7 million across 5 years, with a median of $9.7 million in 2025.
• Annual changes were most pronounced in 2022 — Research & Development soared 57.54% — and 2024, when it decreased 17.59%.
• Cytek Biosciences' Research & Development stood at $9.7 million in 2022, then grew by 11.51% to $10.9 million in 2023, then fell by 10.54% to $9.7 million in 2024, then dropped by 7.83% to $9.0 million in 2025, then gained by 7.16% to $9.6 million in 2026.
• The last three Research & Development figures came in at $9.6 million (Q1 2026), $9.0 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.